- 阻害剤
- 研究分野別
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- 化合物ライブラリー
- 抗体
- 新製品
- お問い合わせ
PD173074
PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src. PD173074 reduces proliferation and promotes apoptosis in gastric cancer cells.
CAS No. 219580-11-7
文献中Selleckの製品使用例（123）
製品安全説明書
現在のバッチを見る：
純度：
99.72%
99.72
PD173074関連製品
シグナル伝達経路
FGFR阻害剤の選択性比較
Cell Data
| Cell Lines | Assay Type | Concentration | Incubation Time | 活性情報 | PMID |
|---|---|---|---|---|---|
| HUVEC | Function assay | 10 nM | 14 hrs | Inhibition of FGFR-mediated angiogenesis in human HUVEC cells assessed as decrease in capillary tube sprouting at 10 nM after 14 hrs | 16474387 |
| HUVEC | Function assay | 100 nM | 14 hrs | Inhibition of FGFR-mediated angiogenesis in human HUVEC cells assessed as decrease in capillary tube sprouting at 100 nM after 14 hrs | 16474387 |
| SUM52 | Antiproliferative assay | 5 days | Antiproliferative activity against human FGFR2-amplified SUM52 cells after 5 days by SRB assay, IC50 = 0.0123 μM. | 28521156 | |
| RT112 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human RT112 cells after 72 hrs by MTT assay, GI50 = 0.015 μM. | 27599742 | |
| insect cells | Function assay | 10 mins | Inhibition of recombinant full length human FGFR1 expressed in baculovirus infected insect cells in presence of [gamma-32P]ATP after 10 mins by scintillation counting based radioactive filter binding assay, IC50 = 0.0215 μM. | 27914362 | |
| SW780 | Antiproliferative assay | 5 days | Antiproliferative activity against human FGFR3-amplified SW780 cells after 5 days by SRB assay, IC50 = 0.0843 μM. | 28521156 | |
| NIH/ 3T3 | Function assay | 5 mins | Inhibition of VEGFR2 (unknown origin) overexpressed in mouse NIH/ 3T3 cells incubated for 5 mins followed by stimulation with VEGF for 5 mins by immunoblotting analysis, IC50 = 0.1 μM. | 27326339 | |
| NCI-H520 | Antiproliferative assay | 7 days | Antiproliferative activity against human FGFR1-amplified NCI-H520 cells after 7 days by SRB assay, IC50 = 0.281 μM. | 28521156 | |
| SK-MEL-30 | Growth Inhibition Assay | IC50=10.8901 μM | SANGER | ||
| KU812 | Growth Inhibition Assay | IC50=10.7391 μM | SANGER | ||
| BE-13 | Growth Inhibition Assay | IC50=10.6576 μM | SANGER | ||
| OAW-42 | Growth Inhibition Assay | IC50=10.5267 μM | SANGER | ||
| SW948 | Growth Inhibition Assay | IC50=10.1882 μM | SANGER | ||
| EM-2 | Growth Inhibition Assay | IC50=10.1393 μM | SANGER | ||
| CAS-1 | Growth Inhibition Assay | IC50=9.97659 μM | SANGER | ||
| IST-MES1 | Growth Inhibition Assay | IC50=9.94534 μM | SANGER | ||
| EW-13 | Growth Inhibition Assay | IC50=9.89055 μM | SANGER | ||
| ES4 | Growth Inhibition Assay | IC50=9.50595 μM | SANGER | ||
| HOS | Growth Inhibition Assay | IC50=9.35134 μM | SANGER | ||
| NCI-H446 | Growth Inhibition Assay | IC50=9.29526 μM | SANGER | ||
| DBTRG-05MG | Growth Inhibition Assay | IC50=9.09607 μM | SANGER | ||
| D-283MED | Growth Inhibition Assay | IC50=9.06534 μM | SANGER | ||
| TE-6 | Growth Inhibition Assay | IC50=8.75143 μM | SANGER | ||
| SW954 | Growth Inhibition Assay | IC50=8.69786 μM | SANGER | ||
| NCI-H520 | Growth Inhibition Assay | IC50=8.62157 μM | SANGER | ||
| LB1047-RCC | Growth Inhibition Assay | IC50=8.52212 μM | SANGER | ||
| COR-L88 | Growth Inhibition Assay | IC50=8.50981 μM | SANGER | ||
| SK-NEP-1 | Growth Inhibition Assay | IC50=8.48149 μM | SANGER | ||
| DB | Growth Inhibition Assay | IC50=8.11504 μM | SANGER | ||
| ES8 | Growth Inhibition Assay | IC50=7.69626 μM | SANGER | ||
| HAL-01 | Growth Inhibition Assay | IC50=7.48341 μM | SANGER | ||
| SK-MEL-28 | Growth Inhibition Assay | IC50=7.37819 μM | SANGER | ||
| ME-180 | Growth Inhibition Assay | IC50=7.10404 μM | SANGER | ||
| J-RT3-T3-5 | Growth Inhibition Assay | IC50=7.07764 μM | SANGER | ||
| SK-UT-1 | Growth Inhibition Assay | IC50=6.91784 μM | SANGER | ||
| MV-4-11 | Growth Inhibition Assay | IC50=6.76626 μM | SANGER | ||
| A4-Fuk | Growth Inhibition Assay | IC50=6.73142 μM | SANGER | ||
| TE-12 | Growth Inhibition Assay | IC50=6.72671 μM | SANGER | ||
| NCI-H1355 | Growth Inhibition Assay | IC50=6.41733 μM | SANGER | ||
| CHP-134 | Growth Inhibition Assay | IC50=6.25182 μM | SANGER | ||
| ML-2 | Growth Inhibition Assay | IC50=6.24977 μM | SANGER | ||
| SF126 | Growth Inhibition Assay | IC50=6.21406 μM | SANGER | ||
| NCI-H1770 | Growth Inhibition Assay | IC50=5.95032 μM | SANGER | ||
| NOS-1 | Growth Inhibition Assay | IC50=5.72927 μM | SANGER | ||
| HuO9 | Growth Inhibition Assay | IC50=5.38843 μM | SANGER | ||
| SK-MEL-3 | Growth Inhibition Assay | IC50=5.2406 μM | SANGER | ||
| L-363 | Growth Inhibition Assay | IC50=4.96665 μM | SANGER | ||
| IGROV-1 | Growth Inhibition Assay | IC50=4.87168 μM | SANGER | ||
| NCI-H209 | Growth Inhibition Assay | IC50=4.58283 μM | SANGER | ||
| KM-H2 | Growth Inhibition Assay | IC50=4.55222 μM | SANGER | ||
| GI-ME-N | Growth Inhibition Assay | IC50=4.5481 μM | SANGER | ||
| LAMA-84 | Growth Inhibition Assay | IC50=4.5331 μM | SANGER | ||
| D-336MG | Growth Inhibition Assay | IC50=4.46817 μM | SANGER | ||
| CAL-72 | Growth Inhibition Assay | IC50=4.41746 μM | SANGER | ||
| LU-139 | Growth Inhibition Assay | IC50=4.31534 μM | SANGER | ||
| A704 | Growth Inhibition Assay | IC50=4.28723 μM | SANGER | ||
| EW-3 | Growth Inhibition Assay | IC50=3.98923 μM | SANGER | ||
| SW780 | Growth Inhibition Assay | IC50=3.92245 μM | SANGER | ||
| A204 | Growth Inhibition Assay | IC50=3.92075 μM | SANGER | ||
| ES5 | Growth Inhibition Assay | IC50=3.83637 μM | SANGER | ||
| CTB-1 | Growth Inhibition Assay | IC50=3.80051 μM | SANGER | ||
| Hs-578-T | Growth Inhibition Assay | IC50=3.67873 μM | SANGER | ||
| LK-2 | Growth Inhibition Assay | IC50=3.67133 μM | SANGER | ||
| CHL-1 | Growth Inhibition Assay | IC50=3.65799 μM | SANGER | ||
| NBsusSR | Growth Inhibition Assay | IC50=3.63969 μM | SANGER | ||
| CCRF-CEM | Growth Inhibition Assay | IC50=3.50488 μM | SANGER | ||
| RO82-W-1 | Growth Inhibition Assay | IC50=3.49855 μM | SANGER | ||
| HH | Growth Inhibition Assay | IC50=3.47676 μM | SANGER | ||
| GAMG | Growth Inhibition Assay | IC50=3.46576 μM | SANGER | ||
| RPMI-8226 | Growth Inhibition Assay | IC50=3.23447 μM | SANGER | ||
| NCI-H1092 | Growth Inhibition Assay | IC50=3.1969 μM | SANGER | ||
| RH-18 | Growth Inhibition Assay | IC50=3.19598 μM | SANGER | ||
| NKM-1 | Growth Inhibition Assay | IC50=3.13564 μM | SANGER | ||
| G-402 | Growth Inhibition Assay | IC50=3.12727 μM | SANGER | ||
| NTERA-S-cl-D1 | Growth Inhibition Assay | IC50=3.03472 μM | SANGER | ||
| MG-63 | Growth Inhibition Assay | IC50=2.94262 μM | SANGER | ||
| KARPAS-45 | Growth Inhibition Assay | IC50=2.70747 μM | SANGER | ||
| 697 | Growth Inhibition Assay | IC50=2.65331 μM | SANGER | ||
| MPP-89 | Growth Inhibition Assay | IC50=2.48364 μM | SANGER | ||
| G-401 | Growth Inhibition Assay | IC50=2.47189 μM | SANGER | ||
| HCC2218 | Growth Inhibition Assay | IC50=2.37939 μM | SANGER | ||
| NCI-H720 | Growth Inhibition Assay | IC50=2.21283 μM | SANGER | ||
| NCI-SNU-1 | Growth Inhibition Assay | IC50=2.18394 μM | SANGER | ||
| H9 | Growth Inhibition Assay | IC50=2.14306 μM | SANGER | ||
| SBC-1 | Growth Inhibition Assay | IC50=2.094 μM | SANGER | ||
| A172 | Growth Inhibition Assay | IC50=1.70355 μM | SANGER | ||
| DU-145 | Growth Inhibition Assay | IC50=1.58217 μM | SANGER | ||
| MSTO-211H | Growth Inhibition Assay | IC50=1.47378 μM | SANGER | ||
| DMS-114 | Growth Inhibition Assay | IC50=1.36737 μM | SANGER | ||
| RS4-11 | Growth Inhibition Assay | IC50=1.33886 μM | SANGER | ||
| HuH-7 | Growth Inhibition Assay | IC50=1.24464 μM | SANGER | ||
| MFE-280 | Growth Inhibition Assay | IC50=0.85872 μM | SANGER | ||
| BV-173 | Growth Inhibition Assay | IC50=0.84623 μM | SANGER | ||
| SW962 | Growth Inhibition Assay | IC50=0.78988 μM | SANGER | ||
| D-263MG | Growth Inhibition Assay | IC50=0.71159 μM | SANGER | ||
| NEC8 | Growth Inhibition Assay | IC50=0.56289 μM | SANGER | ||
| RT-112 | Growth Inhibition Assay | IC50=0.54701 μM | SANGER | ||
| HuO-3N1 | Growth Inhibition Assay | IC50=0.54653 μM | SANGER | ||
| AN3-CA | Growth Inhibition Assay | IC50=0.40133 μM | SANGER | ||
| H-EMC-SS | Growth Inhibition Assay | IC50=0.34715 μM | SANGER | ||
| ECC10 | Growth Inhibition Assay | IC50=0.33898 μM | SANGER | ||
| EoL-1-cell | Growth Inhibition Assay | IC50=0.32984 μM | SANGER | ||
| MFM-223 | Growth Inhibition Assay | IC50=0.21576 μM | SANGER | ||
| KG-1 | Growth Inhibition Assay | IC50=0.05129 μM | SANGER | ||
| NCI-H1581 | Growth Inhibition Assay | IC50=0.01225 μM | SANGER | ||
| A2780 | Growth Inhibition Assay | IC50=11.0308 μM | SANGER | ||
| TGBC24TKB | Growth Inhibition Assay | IC50=11.0737 μM | SANGER | ||
| GOTO | Growth Inhibition Assay | IC50=11.2084 μM | SANGER | ||
| NCI-H526 | Growth Inhibition Assay | IC50=11.3837 μM | SANGER | ||
| BHT-101 | Growth Inhibition Assay | IC50=11.4456 μM | SANGER | ||
| NCI-H1155 | Growth Inhibition Assay | IC50=11.4947 μM | SANGER | ||
| MCF7 | Growth Inhibition Assay | IC50=11.6167 μM | SANGER | ||
| MKN45 | Growth Inhibition Assay | IC50=11.7993 μM | SANGER | ||
| MOLT-16 | Growth Inhibition Assay | IC50=11.9692 μM | SANGER | ||
| YH-13 | Growth Inhibition Assay | IC50=12.0346 μM | SANGER | ||
| P12-ICHIKAWA | Growth Inhibition Assay | IC50=12.3845 μM | SANGER | ||
| GR-ST | Growth Inhibition Assay | IC50=12.5295 μM | SANGER | ||
| CAKI-1 | Growth Inhibition Assay | IC50=12.791 μM | SANGER | ||
| LXF-289 | Growth Inhibition Assay | IC50=13.0835 μM | SANGER | ||
| MHH-PREB-1 | Growth Inhibition Assay | IC50=13.2704 μM | SANGER | ||
| EW-16 | Growth Inhibition Assay | IC50=13.3187 μM | SANGER | ||
| NCI-H82 | Growth Inhibition Assay | IC50=13.4195 μM | SANGER | ||
| MMAC-SF | Growth Inhibition Assay | IC50=13.4547 μM | SANGER | ||
| COLO-684 | Growth Inhibition Assay | IC50=13.5318 μM | SANGER | ||
| QIMR-WIL | Growth Inhibition Assay | IC50=13.8109 μM | SANGER | ||
| NB69 | Growth Inhibition Assay | IC50=13.9868 μM | SANGER | ||
| NCI-H2291 | Growth Inhibition Assay | IC50=14.4453 μM | SANGER | ||
| MKN7 | Growth Inhibition Assay | IC50=14.6676 μM | SANGER | ||
| HDLM-2 | Growth Inhibition Assay | IC50=15.1286 μM | SANGER | ||
| A253 | Growth Inhibition Assay | IC50=15.3869 μM | SANGER | ||
| SK-LU-1 | Growth Inhibition Assay | IC50=15.9094 μM | SANGER | ||
| MEG-01 | Growth Inhibition Assay | IC50=15.9107 μM | SANGER | ||
| SK-N-DZ | Growth Inhibition Assay | IC50=15.9376 μM | SANGER | ||
| H4 | Growth Inhibition Assay | IC50=16.088 μM | SANGER | ||
| LU-65 | Growth Inhibition Assay | IC50=16.3384 μM | SANGER | ||
| NCI-H1048 | Growth Inhibition Assay | IC50=16.5165 μM | SANGER | ||
| LCLC-97TM1 | Growth Inhibition Assay | IC50=16.5889 μM | SANGER | ||
| CAL-120 | Growth Inhibition Assay | IC50=16.9879 μM | SANGER | ||
| LU-134-A | Growth Inhibition Assay | IC50=17.3391 μM | SANGER | ||
| SK-MEL-1 | Growth Inhibition Assay | IC50=17.7127 μM | SANGER | ||
| NCI-H69 | Growth Inhibition Assay | IC50=17.9307 μM | SANGER | ||
| MC116 | Growth Inhibition Assay | IC50=17.975 μM | SANGER | ||
| UMC-11 | Growth Inhibition Assay | IC50=18.1788 μM | SANGER | ||
| HCC1395 | Growth Inhibition Assay | IC50=18.4301 μM | SANGER | ||
| no-10 | Growth Inhibition Assay | IC50=18.6388 μM | SANGER | ||
| NY | Growth Inhibition Assay | IC50=19.0809 μM | SANGER | ||
| OS-RC-2 | Growth Inhibition Assay | IC50=19.1252 μM | SANGER | ||
| D-423MG | Growth Inhibition Assay | IC50=19.3952 μM | SANGER | ||
| LC-2-ad | Growth Inhibition Assay | IC50=19.7612 μM | SANGER | ||
| DU-4475 | Growth Inhibition Assay | IC50=19.8852 μM | SANGER | ||
| YKG-1 | Growth Inhibition Assay | IC50=19.962 μM | SANGER | ||
| HCC1569 | Growth Inhibition Assay | IC50=20.2624 μM | SANGER | ||
| TYK-nu | Growth Inhibition Assay | IC50=20.2847 μM | SANGER | ||
| DEL | Growth Inhibition Assay | IC50=20.9808 μM | SANGER | ||
| MHH-ES-1 | Growth Inhibition Assay | IC50=21.3597 μM | SANGER | ||
| KARPAS-299 | Growth Inhibition Assay | IC50=21.529 μM | SANGER | ||
| CTV-1 | Growth Inhibition Assay | IC50=21.6172 μM | SANGER | ||
| NCI-H2452 | Growth Inhibition Assay | IC50=22.6677 μM | SANGER | ||
| D-566MG | Growth Inhibition Assay | IC50=22.7601 μM | SANGER | ||
| EFO-27 | Growth Inhibition Assay | IC50=23.0651 μM | SANGER | ||
| NCI-H596 | Growth Inhibition Assay | IC50=23.8527 μM | SANGER | ||
| KS-1 | Growth Inhibition Assay | IC50=24.2759 μM | SANGER | ||
| 8305C | Growth Inhibition Assay | IC50=24.4045 μM | SANGER | ||
| A427 | Growth Inhibition Assay | IC50=25.0323 μM | SANGER | ||
| COLO-800 | Growth Inhibition Assay | IC50=25.1061 μM | SANGER | ||
| SJRH30 | Growth Inhibition Assay | IC50=25.3908 μM | SANGER | ||
| MEL-HO | Growth Inhibition Assay | IC50=25.4319 μM | SANGER | ||
| FTC-133 | Growth Inhibition Assay | IC50=25.8186 μM | SANGER | ||
| SF295 | Growth Inhibition Assay | IC50=26.296 μM | SANGER | ||
| SW1710 | Growth Inhibition Assay | IC50=26.4123 μM | SANGER | ||
| EFM-19 | Growth Inhibition Assay | IC50=26.8145 μM | SANGER | ||
| NB10 | Growth Inhibition Assay | IC50=28.2297 μM | SANGER | ||
| TK10 | Growth Inhibition Assay | IC50=28.2399 μM | SANGER | ||
| D-502MG | Growth Inhibition Assay | IC50=28.4 μM | SANGER | ||
| EW-18 | Growth Inhibition Assay | IC50=28.4386 μM | SANGER | ||
| VMRC-RCZ | Growth Inhibition Assay | IC50=28.941 μM | SANGER | ||
| Ca9-22 | Growth Inhibition Assay | IC50=29.4557 μM | SANGER | ||
| KYSE-70 | Growth Inhibition Assay | IC50=29.5786 μM | SANGER | ||
| A101D | Growth Inhibition Assay | IC50=29.6472 μM | SANGER | ||
| WM-115 | Growth Inhibition Assay | IC50=29.7607 μM | SANGER | ||
| HCC2157 | Growth Inhibition Assay | IC50=29.8807 μM | SANGER | ||
| TE-9 | Growth Inhibition Assay | IC50=29.8865 μM | SANGER | ||
| K-562 | Growth Inhibition Assay | IC50=30.0933 μM | SANGER | ||
| SN12C | Growth Inhibition Assay | IC50=30.1426 μM | SANGER | ||
| ESS-1 | Growth Inhibition Assay | IC50=30.4759 μM | SANGER | ||
| K5 | Growth Inhibition Assay | IC50=30.764 μM | SANGER | ||
| J82 | Growth Inhibition Assay | IC50=31.0897 μM | SANGER | ||
| HOP-92 | Growth Inhibition Assay | IC50=31.1111 μM | SANGER | ||
| NCI-H2228 | Growth Inhibition Assay | IC50=31.3296 μM | SANGER | ||
| OCI-AML2 | Growth Inhibition Assay | IC50=31.361 μM | SANGER | ||
| NCI-SNU-5 | Growth Inhibition Assay | IC50=31.8137 μM | SANGER | ||
| A3-KAW | Growth Inhibition Assay | IC50=31.9243 μM | SANGER | ||
| LCLC-103H | Growth Inhibition Assay | IC50=32.0171 μM | SANGER | ||
| KY821 | Growth Inhibition Assay | IC50=32.6884 μM | SANGER | ||
| JVM-2 | Growth Inhibition Assay | IC50=32.9079 μM | SANGER | ||
| Mo-T | Growth Inhibition Assay | IC50=33.1005 μM | SANGER | ||
| IA-LM | Growth Inhibition Assay | IC50=33.275 μM | SANGER | ||
| C8166 | Growth Inhibition Assay | IC50=33.3192 μM | SANGER | ||
| TCCSUP | Growth Inhibition Assay | IC50=33.4307 μM | SANGER | ||
| JEG-3 | Growth Inhibition Assay | IC50=33.4768 μM | SANGER | ||
| MS-1 | Growth Inhibition Assay | IC50=33.5551 μM | SANGER | ||
| NCI-H1304 | Growth Inhibition Assay | IC50=33.5725 μM | SANGER | ||
| Ramos-2G6-4C10 | Growth Inhibition Assay | IC50=34.0335 μM | SANGER | ||
| MDA-MB-453 | Growth Inhibition Assay | IC50=34.6395 μM | SANGER | ||
| KYSE-520 | Growth Inhibition Assay | IC50=34.7181 μM | SANGER | ||
| SW900 | Growth Inhibition Assay | IC50=34.8115 μM | SANGER | ||
| HCC2998 | Growth Inhibition Assay | IC50=35.1529 μM | SANGER | ||
| A2058 | Growth Inhibition Assay | IC50=35.6061 μM | SANGER | ||
| OVCAR-3 | Growth Inhibition Assay | IC50=36.2045 μM | SANGER | ||
| MOLT-4 | Growth Inhibition Assay | IC50=36.2294 μM | SANGER | ||
| CAPAN-1 | Growth Inhibition Assay | IC50=36.4699 μM | SANGER | ||
| SCC-9 | Growth Inhibition Assay | IC50=37.4027 μM | SANGER | ||
| SF268 | Growth Inhibition Assay | IC50=38.3433 μM | SANGER | ||
| HGC-27 | Growth Inhibition Assay | IC50=38.3711 μM | SANGER | ||
| DOHH-2 | Growth Inhibition Assay | IC50=38.7158 μM | SANGER | ||
| KE-37 | Growth Inhibition Assay | IC50=38.9828 μM | SANGER | ||
| MOLT-13 | Growth Inhibition Assay | IC50=39.2502 μM | SANGER | ||
| ES1 | Growth Inhibition Assay | IC50=39.385 μM | SANGER | ||
| SK-OV-3 | Growth Inhibition Assay | IC50=39.9643 μM | SANGER | ||
| SNU-449 | Growth Inhibition Assay | IC50=40.0764 μM | SANGER | ||
| KYSE-510 | Growth Inhibition Assay | IC50=40.1295 μM | SANGER | ||
| HL-60 | Growth Inhibition Assay | IC50=40.9783 μM | SANGER | ||
| DJM-1 | Growth Inhibition Assay | IC50=40.9799 μM | SANGER | ||
| TGBC11TKB | Growth Inhibition Assay | IC50=41.0926 μM | SANGER | ||
| U-2-OS | Growth Inhibition Assay | IC50=42.2641 μM | SANGER | ||
| NCI-H2030 | Growth Inhibition Assay | IC50=42.4368 μM | SANGER | ||
| LU-135 | Growth Inhibition Assay | IC50=42.5447 μM | SANGER | ||
| ZR-75-30 | Growth Inhibition Assay | IC50=43.0493 μM | SANGER | ||
| GT3TKB | Growth Inhibition Assay | IC50=43.2679 μM | SANGER | ||
| RPMI-2650 | Growth Inhibition Assay | IC50=43.7816 μM | SANGER | ||
| SAS | Growth Inhibition Assay | IC50=43.9534 μM | SANGER | ||
| MDA-MB-231 | Growth Inhibition Assay | IC50=43.9609 μM | SANGER | ||
| JVM-3 | Growth Inhibition Assay | IC50=44.0533 μM | SANGER | ||
| COLO-320-HSR | Growth Inhibition Assay | IC50=44.5633 μM | SANGER | ||
| SNB75 | Growth Inhibition Assay | IC50=44.6105 μM | SANGER | ||
| NCI-H441 | Growth Inhibition Assay | IC50=44.9328 μM | SANGER | ||
| HCT-116 | Growth Inhibition Assay | IC50=44.9868 μM | SANGER | ||
| NCI-H226 | Growth Inhibition Assay | IC50=45.6368 μM | SANGER | ||
| CAL-33 | Growth Inhibition Assay | IC50=45.9217 μM | SANGER | ||
| NCI-H1437 | Growth Inhibition Assay | IC50=46.321 μM | SANGER | ||
| HCC1187 | Growth Inhibition Assay | IC50=46.4255 μM | SANGER | ||
| NUGC-3 | Growth Inhibition Assay | IC50=46.5709 μM | SANGER | ||
| T98G | Growth Inhibition Assay | IC50=47.547 μM | SANGER | ||
| OVCAR-8 | Growth Inhibition Assay | IC50=47.683 μM | SANGER | ||
| LB2241-RCC | Growth Inhibition Assay | IC50=47.727 μM | SANGER | ||
| NCI-H358 | Growth Inhibition Assay | IC50=48.1152 μM | SANGER | ||
| PANC-08-13 | Growth Inhibition Assay | IC50=48.1853 μM | SANGER | ||
| KP-N-YN | Growth Inhibition Assay | IC50=48.2102 μM | SANGER | ||
| NCI-H1755 | Growth Inhibition Assay | IC50=48.2726 μM | SANGER | ||
| NCI-N87 | Growth Inhibition Assay | IC50=48.2991 μM | SANGER | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
| fibroblast cells | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
| 他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい | |||||
生物活性
| 製品説明 | PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src. PD173074 reduces proliferation and promotes apoptosis in gastric cancer cells. | ||||
|---|---|---|---|---|---|
| Targets |
|
| In Vitro | ||||
| In vitro | PD173074 is an ATP-competitive inhibitor of FGFR1 with Ki of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. [1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. [2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. [3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. [4] | |||
|---|---|---|---|---|
| Kinase Assay | In vitro kinase inhibition assays | |||
| Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl2, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-32P]ATP (5 μM ATP containing 0.4 μCi of [γ-32P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [32P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically. | ||||
| 細胞実験 | 細胞株 | KMS11 and KMS18 | ||
| 濃度 | Dissolved in DMSO, final concentrations ~100 nM | |||
| 反応時間 | 48 hours | |||
| 実験の流れ | Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT. | |||
| 実験結果図 | Methods | Biomarkers | 結果図 | PMID |
| Western blot | pFGFR2 / FGFR2 p-S6RP / p-PRAS40 / p-p105 NFKB / P105 NFKB / P50 NFKB / p-AMPK / p-CRK II / p-PDK1 |
|
24968263 | |
| Growth inhibition assay | Cell viability |
|
24968263 | |
| In Vivo | ||
| In Vivo | Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. [1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. [4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. [5] | |
|---|---|---|
| 動物実験 | 動物モデル | Swiss Webster mice with induced corneal angiogenesis |
| 投与量 | ~2 mg/kg/day | |
| 投与経路 | Administered intraperitoneally | |
化学情報
| 分子量 | 523.67 | 化学式 | C28H41N7O3 |
| CAS No. | 219580-11-7 | SDF | Download PD173074 SDFをダウンロードする |
| Smiles | CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C | ||
| 保管 | |||
|
In vitro |
DMSO : 100 mg/mL ( (190.95 mM)； 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。) Ethanol : 100 mg/mL Water : Insoluble |
モル濃度計算器 |
|
in vivo Add solvents to the product individually and in order. |
投与溶液組成計算機 | ||||
実験計算
投与溶液組成計算機(クリア溶液)
ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）
mg/kg
g
μL
匹
ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結果：
投与溶媒濃度： mg/ml;
DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )
投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH2O，を加え完全に溶解させます。
投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。
注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。
技術サポート
ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。
他に質問がある場合は、お気軽にお問い合わせください。
* 必須
よくある質問（FAQ）
質問1:
What is the half-life of PD173074(S1264) in vivo?
回答
According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.
Tags: PD173074を買う | PD173074 ic50 | PD173074供給者 | PD173074を購入する | PD173074費用 | PD173074生産者 | オーダーPD173074 | PD173074化学構造 | PD173074分子量 | PD173074代理店
納期 国内在庫品：受注日の翌日（15時までの受注分） ＊北海道、九州、沖縄への配送は受注日より２日以上 を要する場合あり 海外在庫品：受注後１〜２週間